Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 7/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 5/20 | 0.50 |
| ▸ | DRD5 | P21918 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17192219 | 0.86 | KCNH2 (0.56) | HTR7DRD2DRD3 | |
| SCHEMBL15748105 | 0.84 | SIGMAR1 (0.56) | HTR7SIGMAR1DRD2DRD5DRD3 | |
| SCHEMBL15747983 | 0.83 | HTR2A (0.64) | HTR7SIGMAR1DRD2DRD5DRD3 | |
| SCHEMBL15748140 | 0.83 | SIGMAR1 (0.53) | HTR7SIGMAR1DRD2DRD5DRD3 | |
| SCHEMBL15748176 | 0.81 | KMT2A (0.53) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL7804944 | 0.79 | DRD2 (0.51) | HTR7SIGMAR1DRD2DRD5DRD3 | |
| Hydrochloric Acid SCHEMBL8021813 | 0.78 | DRD2 (0.50) | HTR7SIGMAR1DRD2DRD5DRD3 | |
| SCHEMBL796721 | 0.76 | HTR7 (0.52) | HTR7SIGMAR1DRD2DRD3 | |
| SCHEMBL12475241 | 0.76 | HTR7 (0.52) | HTR7SIGMAR1DRD2DRD3 | |
| SCHEMBL23902692 | 0.75 | LMNA (0.49) | SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | claimed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | claimed |
| EP-2924033-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd (CN) | 2015-09-30 | — | — | EP | claimed |
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2924033-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd (CN) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079155-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | 辽宁贝雷生物制药有限公司 (CN) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | P2RX5, TBXA2R, CYP3A5 | SERPINE1 1602/4885HTR7 577/4885SIGMAR1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.